RAO R MUSHTAQ
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology THORNTON, CO NPI 1952604381
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology CO E.R. Squibb & Sons, L.L.C. All categories
General Payments — all program years on this page
$37,469.73
- Category: General Payments
- Program years: PY2019–2024
- Record count: 183
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $7,014.53 across 7 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $6,837.50 | 5 |
| Food and Beverage | $177.03 | 2 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,485.00 | 1 |
| Janssen Scientific Affairs, LLC | $1,925.00 | 1 |
| Astellas Pharma Global Development | $1,856.74 | 2 |
| Acerta Pharma LLC | $677.50 | 2 |
| BeiGene USA, Inc. | $70.29 | 1 |
By program year
Records — PY2024 (7)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1078846425 | Janssen Scientific Affairs, LLC | $1,925.00 | 02/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1101579721 | E.R. Squibb & Sons, L.L.C. | $2,485.00 | 12/19/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1104724251 | AstraZeneca Pharmaceuticals LP | $400.00 | 04/27/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1105801476 | AstraZeneca Pharmaceuticals LP | $277.50 | 03/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
| 1120862673 | BeiGene USA, Inc. | $70.29 | 06/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1132966843 | Astellas Pharma Global Development | $106.74 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1132966851 | Astellas Pharma Global Development | $1,750.00 | 05/31/2024 | Consulting Fee | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.